Immunohistochemistry on a human breast cancer tissue microarray (TMA) using a custom-made anti-EDI3 antibody from AMSBIO (clone 3B8G3), showing strong EDI3 positivity.
Dr Rosemarie Marchan of the Leibniz Research Centre for Working Environment & Human Factors at the TU Dortmund in Germany.

Custom monoclonal antibody reveals HER2+ breast cancer target

Sep 07 2023

AMSBIO has supplied a tailor-made monoclonal antibody (mAB) to TU Dortmund researchers in Germany. This mAB aims to decode EDI3's role in breast cancer development, how it's controlled by HER2 signalling, and its therapeutic potential.

HER2+ breast cancer, marked by excessive Human Epidermal Growth Factor Receptor 2 (HER2) expression, is an extremely aggressive cancer subtype. Despite advancements in HER2-targeted therapies, the persistence of treatment resistance, both acquired and inherent, necessitates exploration of alternative therapeutic targets.

Targeting EDI3: A Potential Therapeutic Strategy for HER2-Positive Breast Cancer

Under the leadership of Dr Rosemarie Marchan, a group of researchers has undertaken an extensive study to investigate the clinical significance of EDI3, a glycerophosphodiesterase enzyme linked to choline metabolism, within HER2-positive breast cancer. They utilised the custom monoclonal antibody against EID3, provided by AMSBIO, in their research.

Dr Marchan commented: “We have tested many off-the-shelf antibodies over the years, with little to no success. We have also contracted companies to create a custom antibody for us, but again with limited success. Therefore, we are very thankful a few years ago that we were able to get a great antibody against EID3 from AMSBIO. Using this precious antibody our team has been able to demonstrate that inhibiting EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.”

Read the full case study describing the work of Dr Marchan and her team in the Leibniz Research Centre for Working Environment and Human Factors (IfADo) at the TU Dortmund.

Monoclonal Antibody Service

With a track record of providing products to numerous industrial and academic projects over the past two decades, AMSBIO has gained widespread recognition as a leading supplier of both ready-made and tailored antibodies. Their services encompass the creation of custom monoclonal antibodies tailored to your specific target antigen, delivering a well-informed and high-quality solution.

More information online